We’re engineering previously unimaginable biological

learn how >

Our Platform

Poor targeting of oncology therapeutics damages healthy organs and tissues, resulting in reduced quality of life for patients due to severe side effects, limited efficacy, early treatment discontinuation, and reduced survival.

9Bio’s computationally-guided structural biology platform enhances the clinical impact of targeted cancer therapies by integrating tumor biochemistry to design drugs that selectively target tumors based on the unique metabolomic and chemical signatures of the cancer microenvironment, while sparing healthy tissues.

This technology generates safer and more efficacious therapeutics, paving the way for novel and highly targeted cancer treatments. Our pipeline of three discovery-stage therapies illustrates the broad applicability of our approach.

Antibody example

BENEFITS

Reduced side-effects

The specificity conferred by our platform reduces peripheral toxicity while maintaining strong anti-cancer effects.

Improved efficacy via superior bioavailability

By limiting target engagement outside tumors, we avoid premature clearance from the body, leading to longer retention and better bioavailability within tumors. This can improve both dosing schedule and efficacy.

Broadened range of druggable targets in precision oncology (e.g., ADCs)

By minimizing off-tumor target engagement, we can develop precision-targeted therapies such as antibody-drug conjugates (ADCs) for tumor antigens previously deemed undruggable due to partial peripheral expression.

Novel modalities

Our platform enables the exploration of mechanisms of action that would be too toxic in healthy tissues. This includes harnessing underexploited immune effector mechanisms, pioneering new classes of therapeutics.

Collaborations

9Bio recognizes the value of strategic collaborations. We are excited to establish new collaborations that leverage our technology to develop innovative protein-based therapeutics, including antibodies, engineered cytokines, CAR T cells, and ligand/receptor mimetics.